Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,974 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells.
Pardanani A, Lasho T, Chen D, Kimlinger TK, Finke C, Zblewski D, Patnaik MM, Reichard KK, Rowinsky E, Hanson CA, Brooks C, Tefferi A. Pardanani A, et al. Among authors: brooks c. Leukemia. 2015 Jul;29(7):1605-8. doi: 10.1038/leu.2015.16. Epub 2015 Feb 2. Leukemia. 2015. PMID: 25640886 No abstract available.
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N. Mani R, et al. Among authors: brooks c. Haematologica. 2018 Aug;103(8):1288-1297. doi: 10.3324/haematol.2018.188193. Epub 2018 May 17. Haematologica. 2018. PMID: 29773600 Free PMC article.
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, Weinstock DM, Montero J, Aster JC, Johannessen CM, Lane AA. Togami K, et al. Among authors: brooks cl. J Clin Invest. 2019 Nov 1;129(11):5005-5019. doi: 10.1172/JCI128571. J Clin Invest. 2019. PMID: 31437130 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36163847
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F. Angelot-Delettre F, et al. Among authors: brooks c. Haematologica. 2015 Feb;100(2):223-30. doi: 10.3324/haematol.2014.111740. Epub 2014 Nov 7. Haematologica. 2015. PMID: 25381130 Free PMC article.
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M. Han L, et al. Among authors: brooks c. Clin Cancer Res. 2017 Jul 1;23(13):3385-3395. doi: 10.1158/1078-0432.CCR-16-1904. Epub 2017 Jan 17. Clin Cancer Res. 2017. PMID: 28096272 Free PMC article.
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Frankel AE, et al. Among authors: brooks c. Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23. Blood. 2014. PMID: 24859366 Free PMC article. Clinical Trial.
1,974 results